Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06372210 · ClinicalTrials.gov registry record · NA
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
A NA study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT06372210: Completed NA study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT06372210 is a NA study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06372210, a NA study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
Primary Outcome
The PDA is calculated as the number of total positive detections by patch divided by the number of the total DOIs. PDA was estimated by Clopper-Pearson method.
Interventions
- DRUG Placebo IEM tablet
- DRUG Abilify MyCite®
- DEVICE D-Tect Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2023-07-19 |
| Phase | NA |
What the finished NCT06372210 record still lists
NCT06372210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo IEM tablet is the first listed.
NCT06372210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06372210 about?
NCT06372210 is a clinical study titled "A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion". The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
What is the current status of trial NCT06372210?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2023-06-26. Estimated completion is 2023-07-19.
What interventions are being tested in trial NCT06372210?
The interventions under investigation include: Placebo IEM tablet (DRUG), Abilify MyCite® (DRUG), D-Tect Patch (DEVICE).
Who is sponsoring clinical trial NCT06372210?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06372210's enrollment target sits among peer trials
54 1268th of 2000 higher than 730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI